MYL and TEVA recently launched a generic version of AGN's Estrace. Estrace represents 3% of AGN's total revenue. AGN already faces a generic threat for Restasis (9% of revenue). Generic threats and no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback